Advertisement


Rebecca H. Johnson, MD, on Fertility Preservation and Cancer

2015 NCCN Annual Conference

Advertisement

Although guidelines worldwide mandate fertility preservation for newly diagnosed patients within their reproductive window, most patients are still not referred or offered this option. Rebecca H. Johnson, MD, of Mary Bridge Children’s Hospital, explains the steps that need to be taken when counseling patients.



Related Videos

Lung Cancer

Thomas A. D’Amico, MD, on Diagnosis and Treatment of NSCLC Using Minimally Invasive Techniques

Thomas A. D’Amico, MD, of Duke Cancer Institute, discusses the superior efficacy of thoracoscopic lobectomy. This minimally invasive procedure is used in only 50% of lung cancer surgeries in the United States, in 30% of procedures in Asia, and in as few as 10% to 20% of procedures in Europe.

Gynecologic Cancers

Wui-Jin Koh, MD, on Making NCCN Guidelines Relevant Around the Globe

Wui-Jin Koh, MD, of the Fred Hutchinson Cancer Research Center and the Seattle Cancer Care Alliance, discusses the program to adapt NCCN guidelines to regions of the world with different resource availability. The first guideline to be adapted in this way is for cervical cancer, which is prevalent in the developing world.

Survivorship

Crystal S. Denlinger, MD, on Management of Anthracycline-Induced Cardiac Toxicity

Crystal S. Denlinger, MD, of Fox Chase Cancer Center, discusses cardiac toxicities in cancer survivors, a new topic for the NCCN Survivorship Guidelines this year, and the need for more research on this important side effect, including prevention and surveillance.

Kidney Cancer

Eric Jonasch, MD, on Kidney Cancer: Current and Novel Treatment Options

Eric Jonasch, MD, of The University of Texas, MD Anderson Cancer Center, discusses the progress being made in kidney cancer treatment and the clinical trials that focused on sunitinib, sorafenib, and everolimus, among others.

Multiple Myeloma

Kenneth C. Anderson, MD, on Multiple Myeloma: Current Treatment Approaches and Future Directions

Kenneth C. Anderson, MD, of Dana-Farber/Brigham and Women’s Cancer Center, discusses the incredible progress made in treating multiple myeloma, with nine therapeutic options approved in the past decade, two drugs approved this year, and a number of new options on the horizon.

Advertisement

Advertisement




Advertisement